Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 30;23(13):7302.
doi: 10.3390/ijms23137302.

Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives

Affiliations
Review

Ion Channels in Multiple Myeloma: Pathogenic Role and Therapeutic Perspectives

Ilaria Saltarella et al. Int J Mol Sci. .

Abstract

Ion channels are pore-forming proteins that allow ions to flow across plasma membranes and intracellular organelles in both excitable and non-excitable cells. They are involved in the regulation of several biological processes (i.e., proliferation, cell volume and shape, differentiation, migration, and apoptosis). Recently, the aberrant expression of ion channels has emerged as an important step of malignant transformation, tumor progression, and drug resistance, leading to the idea of "onco-channelopathy". Here, we review the contribution of ion channels and transporters in multiple myeloma (MM), a hematological neoplasia characterized by the expansion of tumor plasma cells (MM cells) in the bone marrow (BM). Deregulation of ion channels sustains MM progression by modulating intracellular pathways that promote MM cells' survival, proliferation, and drug resistance. Finally, we focus on the promising role of ion channels as therapeutic targets for the treatment of MM patients in a combination strategy with currently used anti-MM drugs to improve their cytotoxic activity and reduce adverse effects.

Keywords: drug resistance; ion channels; multiple myeloma; therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of ion channels/exchangers expressed in MM cells, which may be involved in MM pathogenesis and drug resistance.

References

    1. Kumar S.K., Rajkumar V., Kyle R.A., van Duin M., Sonneveld P., Mateos M.V., Gay F., Anderson K.C. Multiple myeloma. Nat. Rev. Dis. Prim. 2017;3:17046. doi: 10.1038/nrdp.2017.46. - DOI - PubMed
    1. Mateos M.V., Landgren O. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treat. Res. 2016;169:3–12. doi: 10.1007/978-3-319-40320-5_1. - DOI - PubMed
    1. Manier S., Sacco A., Leleu X., Ghobrial I.M., Roccaro A.M. Bone marrow microenvironment in multiple myeloma progression. J. Biomed. Biotechnol. 2012;2012:157496. doi: 10.1155/2012/157496. - DOI - PMC - PubMed
    1. Di Marzo L., Desantis V., Solimando A.G., Ruggieri S., Annese T., Nico B., Fumarulo R., Vacca A., Frassanito M.A. Microenvironment drug resistance in multiple myeloma: Emerging new players. Oncotarget. 2016;7:60698–60711. doi: 10.18632/oncotarget.10849. - DOI - PMC - PubMed
    1. Gadsby D.C. Ion channels versus ion pumps: The principal difference, in principle. Nat. Rev. Mol. Cell Biol. 2009;10:344–352. doi: 10.1038/nrm2668. - DOI - PMC - PubMed